CatalYm GmbH

Privately held: no public share price · Germany

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2
GDF-15Monoclonal antibody
Non-Small Cell Lung CancerBladder Cancer

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
April 2028 (1)
VisugromabPhase 1/2Solid Tumor, Adult
Est. primary completion 2028-04-30 · NCT04725474 · CT.gov ↗
What to watch
2029 (4)
March 2029 (1)
VisugromabPhase 2Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
Est. primary completion 2029-03-31 · NCT07098988 · CT.gov ↗
What to watch
September 2029 (1)
VisugromabPhase 2Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma …
Est. primary completion 2029-09 · NCT07219459 · CT.gov ↗
What to watch
October 2029 (1)
VisugromabPhase 2Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
Est. primary completion 2029-10-01 · NCT07246863 · CT.gov ↗
What to watch
December 2029 (1)
VisugromabPhase 2/3Cancer-associated Cachexia
Est. primary completion 2029-12 · NCT07112196 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.